Tag: exemestaneAromasin
Exemestane: Trade name Aromasin. Exemestane is an aromatase inhibitor used to treat ER+ breast cancer. Aromatase inhibitors are designed to inhibit the action of the enzyme aromatase, which converts androgens into estrogens within the body.
Articles
News
09/08/13
Not completing anti-estrogen treatment linked to sharply higher risk of recurrence 04/30/13
Unpleasant side effects of anti-estrogens can indicate treatment is working 07/15/12
Reduction in breast density shows endocrine treatment is working 07/17/11
Increasingly severe side effects of aromatase inhibitors may make tamoxifen first the best strategy 03/01/11
Aromatase inhibitor only or after tamoxifen are both effective treatments 03/07/10
Weight gain can increase hot flashes in breast cancer survivors on aromatase inhibitors 02/13/10
Tamoxifen treatment results in cognitive impairment compared to Aromasin 01/22/10
Treatment with aromatase inhibitors results in better breast cancer outcomes than tamoxifen
Studies
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial Long-Term Follow-Up of the Intergroup Exemestane Study Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04) Differential profile of letrozole and exemestane on bone turnover markers in vinyl cyclohexene diepoxide treated ovotoxic female mice Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer Exemestane use in postmenopausal women at high risk for invasive breast cancer: evaluating biomarkers of efficacy and safety New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial Synergistic effects of exemestane and aspirin on mcf-7 human breast cancer cells Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - A TEAM study analysis Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients Postmenopausal Women with DCIS Post-Mastectomy: A Potential Role for Aromatase Inhibitors Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation Patient-Reported Predictors of Early Treatment Discontinuation: NCIC JMA.27/E1Z03 Quality of Life Study of Postmenopausal Women with Primary Breast Cancer Randomized to Exemestane or Anastrozole The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
TOP